Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Sep 2025 value amounting to $1.1 million.

  • Insight Molecular Diagnostics' Capital Expenditures rose 1106.90% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 239.22%. This contributed to the annual value of $516,000 for FY2024, which is 83.63% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Capital Expenditures stood at $1.1 million, which was up 200.86% from $349,000 recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Capital Expenditures high stood at $1.6 million for Q1 2022, and its period low was -$564,000 during Q3 2023.
  • Over the past 3 years, Insight Molecular Diagnostics' median Capital Expenditures value was $214,000 (recorded in 2024), while the average stood at $213,556.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Capital Expenditures skyrocketed by 1,813.64% in 2021, and later plummeted by 165.66% in 2023.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Capital Expenditures stood at $401,000 in 2021, then surged by 100.00% to $802,000 in 2022, then plummeted by 67.08% to $264,000 in 2023, then dropped by 18.94% to $214,000 in 2024, then skyrocketed by 1,106.90% to $1.1 million in 2025.
  • Its Capital Expenditures was $1.1 million in Q3 2025, compared to $349,000 in Q2 2025 and $307,000 in Q1 2025.